Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2013 1
2016 2
2017 1
2018 1
2019 1
2020 2
2023 1
2025 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
The pipeline for drugs for control and elimination of neglected tropical diseases: 2. Oral anti-infective drugs and drug combinations for off-label use.
Pfarr KM, Krome AK, Al-Obaidi I, Batchelor H, Vaillant M, Hoerauf A, Opoku NO, Kuesel AC. Pfarr KM, et al. Parasit Vectors. 2023 Oct 31;16(1):394. doi: 10.1186/s13071-023-05909-8. Parasit Vectors. 2023. PMID: 37907954 Free PMC article. Review.
Oral drugs evaluated include sparfloxacin and acedapsone for leprosy; rifampicin, rifapentin and moxifloxacin for onchocerciasis; imatinib and levamisole for loiasis; itraconazole, fluconazole, ketoconazole, posaconazole, ravuconazole and disulfiram for Chagas disease, dox …
Oral drugs evaluated include sparfloxacin and acedapsone for leprosy; rifampicin, rifapentin and moxifloxacin for onchocerciasis; imatinib a …
Pharmacologic interventions for alcohol use disorder.
Menge J, Evitt B. Menge J, et al. JAAPA. 2025 Jun 1;38(6):e2-e6. doi: 10.1097/01.JAA.0000000000000106. Epub 2025 May 27. JAAPA. 2025. PMID: 40421949 Review.
It is therefore important to examine multiple avenues for successful cessation and continued abstinence. Disulfiram, oral naltrexone, naltrexone IM, and acamprosate are currently the only four medications approved for the treatment of AUD by the FDA. ...
It is therefore important to examine multiple avenues for successful cessation and continued abstinence. Disulfiram, oral naltrexone, …
Pharmacotherapy of alcoholism - an update on approved and off-label medications.
Soyka M, Müller CA. Soyka M, et al. Expert Opin Pharmacother. 2017 Aug;18(12):1187-1199. doi: 10.1080/14656566.2017.1349098. Epub 2017 Jul 24. Expert Opin Pharmacother. 2017. PMID: 28658981 Review.
Expert opinion: Acamprosate, naltrexone, nalmefene and disulfiram are the only approved 'alcohol-specific' drugs. Acamprosate and naltrexone have been evaluated in numerous clinical trials and represent evidence-based treatments in AUDs. Nalmefene use, however, is controve …
Expert opinion: Acamprosate, naltrexone, nalmefene and disulfiram are the only approved 'alcohol-specific' drugs. Acamprosate and nal …
Evidence-Based Pharmacotherapies for Alcohol Use Disorder: Clinical Pearls.
Fairbanks J, Umbreit A, Kolla BP, Karpyak VM, Schneekloth TD, Loukianova LL, Sinha S. Fairbanks J, et al. Mayo Clin Proc. 2020 Sep;95(9):1964-1977. doi: 10.1016/j.mayocp.2020.01.030. Epub 2020 May 20. Mayo Clin Proc. 2020. PMID: 32446635 Review.
There are three medications approved for the treatment of alcohol use disorder by the US Food and Drug Administration (FDA): disulfiram, naltrexone (oral and long-acting injectable), and acamprosate. Of growing interest is the use of anticonvulsants for the treatment of al …
There are three medications approved for the treatment of alcohol use disorder by the US Food and Drug Administration (FDA): disulfiram …
Medical treatment of alcohol dependence: a systematic review.
Miller PM, Book SW, Stewart SH. Miller PM, et al. Int J Psychiatry Med. 2011;42(3):227-66. doi: 10.2190/PM.42.3.b. Int J Psychiatry Med. 2011. PMID: 22439295 Free PMC article.
Acamprosate shows modest efficacy with recently abstinent patients, with European studies showing better results than U.S. ones. The evidence-base for disulfiram is equivocal. Depot naltrexone shows efficacy (25% greater reduction in rate of heavy drinking vs. placebo, in …
Acamprosate shows modest efficacy with recently abstinent patients, with European studies showing better results than U.S. ones. The evidenc …
Potential medications for the treatment of alcohol use disorder: An evaluation of clinical efficacy and safety.
Litten RZ, Wilford BB, Falk DE, Ryan ML, Fertig JB. Litten RZ, et al. Subst Abus. 2016 Apr-Jun;37(2):286-98. doi: 10.1080/08897077.2015.1133472. Subst Abus. 2016. PMID: 26928397 Review.
To date, 3 medications have been approved by the US Food and Drug Administration (FDA) to treat alcohol dependence: disulfiram, naltrexone, and acamprosate. In addition to these approved medications, researchers have identified new therapeutic targets and, as a result, a n …
To date, 3 medications have been approved by the US Food and Drug Administration (FDA) to treat alcohol dependence: disulfiram, naltr …
Pharmacotherapy for Alcohol Dependence: The 2015 Recommendations of the French Alcohol Society, Issued in Partnership with the European Federation of Addiction Societies.
Rolland B, Paille F, Gillet C, Rigaud A, Moirand R, Dano C, Dematteis M, Mann K, Aubin HJ. Rolland B, et al. CNS Neurosci Ther. 2016 Jan;22(1):25-37. doi: 10.1111/cns.12489. CNS Neurosci Ther. 2016. PMID: 26768685 Free PMC article.
For relapse prevention, acamprosate and naltrexone are recommended as first-line medications (grade A). Disulfiram can be proposed as second-line option in patients with sufficient information and supervision (EC). ...In a stabilized pregnant patient taking medication to s …
For relapse prevention, acamprosate and naltrexone are recommended as first-line medications (grade A). Disulfiram can be proposed as …
Prescription of topiramate to treat alcohol use disorders in the Veterans Health Administration.
Del Re AC, Gordon AJ, Lembke A, Harris AH. Del Re AC, et al. Addict Sci Clin Pract. 2013 Jul 8;8(1):12. doi: 10.1186/1940-0640-8-12. Addict Sci Clin Pract. 2013. PMID: 23835352 Free PMC article.
BACKGROUND: As a quality improvement metric, the US Veterans Health Administration (VHA) monitors the proportion of patients with alcohol use disorders (AUD) who receive FDA approved medications for alcohol dependence (naltrexone, acamprosate, and disulfiram). Evidence sup …
BACKGROUND: As a quality improvement metric, the US Veterans Health Administration (VHA) monitors the proportion of patients with alcohol us …
Pharmacological treatment of alcohol use disorder. Scientific evidence.
Attilia F, Perciballi R, Rotondo C, Capriglione I, Iannuzzi S, Attilia ML, Vitali M, Alessandrini G, Scamporrino MCM, Fiore M, Ceccanti M; Interdisciplinary Study Group CRARL - SITAC - SIPaD - SITD - SIPDip. Attilia F, et al. Riv Psichiatr. 2018 May-Jun;53(3):123-127. doi: 10.1708/2925.29414. Riv Psichiatr. 2018. PMID: 29912214
While non-drug treatment is evolving, from a medical perspective few pharmacotherapies are available; in particular acamprosate, naltrexone and more recently nalmefene among anticraving drugs, disulfiram as an antidipsotropic medication. New studies are focusing on off-lab …
While non-drug treatment is evolving, from a medical perspective few pharmacotherapies are available; in particular acamprosate, naltrexone …